Latest Insider Transactions at Vir Biotechnology, Inc. (VIR)
This section provides a real-time view of insider transactions for Vir Biotechnology, Inc. (VIR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Vir Biotechnology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Vir Biotechnology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 01
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
4,176
+33.34%
|
-
|
|
Apr 01
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-1.78%
|
-
|
|
Apr 01
2021
|
Robert Nelsen Director |
BUY
Other acquisition or disposition
|
Direct |
5,987
+33.33%
|
-
|
|
Apr 01
2021
|
Robert Nelsen Director |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-1.78%
|
-
|
|
Mar 30
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
4,174
+50.0%
|
-
|
|
Mar 30
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-1.74%
|
-
|
|
Mar 30
2021
|
Robert Nelsen Director |
BUY
Other acquisition or disposition
|
Direct |
5,989
+50.0%
|
-
|
|
Mar 30
2021
|
Robert Nelsen Director |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-1.74%
|
-
|
|
Mar 29
2021
|
Ann M. Hanly EVP & Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
Mar 23
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
7,900
-9.62%
|
$418,700
$53.6 P/Share
|
|
Mar 23
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,900
+8.78%
|
$7,900
$1.53 P/Share
|
|
Mar 10
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,340
-3.06%
|
$112,320
$48.0 P/Share
|
|
Mar 10
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,340
+2.97%
|
$2,340
$1.53 P/Share
|
|
Mar 09
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
5,560
-6.97%
|
$244,640
$44.8 P/Share
|
|
Mar 09
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,560
+6.52%
|
$5,560
$1.53 P/Share
|
|
Mar 01
2021
|
Jay Parrish Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,944
-42.85%
|
$437,472
$63.44 P/Share
|
|
Mar 01
2021
|
Jay Parrish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,944
+18.75%
|
$6,944
$1.53 P/Share
|
|
Feb 23
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
7,900
-9.62%
|
$497,700
$63.74 P/Share
|
|
Feb 23
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,900
+18.71%
|
$18,900
$1.53 P/Share
|
|
Feb 16
2021
|
George A Scangos Director |
BUY
Grant, award, or other acquisition
|
Direct |
111,000
+2.35%
|
-
|
|
Feb 16
2021
|
Steven J. Rice Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Feb 16
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,000
+22.65%
|
-
|
|
Feb 16
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+11.46%
|
$0
$0.86 P/Share
|
|
Feb 16
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+32.19%
|
-
|
|
Feb 16
2021
|
Howard Horn CFO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+10.98%
|
-
|
|
Feb 12
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+12.94%
|
$0
$0.86 P/Share
|
|
Feb 09
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
7,900
-19.22%
|
$560,900
$71.16 P/Share
|
|
Feb 09
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,900
+16.12%
|
$7,900
$1.53 P/Share
|
|
Feb 01
2021
|
Jay Parrish Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,944
-3.03%
|
$479,136
$69.91 P/Share
|
|
Feb 01
2021
|
Jay Parrish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,944
+1.5%
|
$6,944
$1.53 P/Share
|
|
Jan 26
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
31,300
-48.53%
|
$1,502,400
$48.17 P/Share
|
|
Jan 26
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
31,300
+32.67%
|
$31,300
$1.53 P/Share
|
|
Jan 15
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
10,530
-24.08%
|
$400,140
$38.0 P/Share
|
|
Jan 15
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,530
+19.41%
|
$10,530
$1.53 P/Share
|
|
Jan 12
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
3,805
-10.28%
|
$110,345
$29.36 P/Share
|
|
Jan 12
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,805
+9.32%
|
$3,805
$1.53 P/Share
|
|
Jan 04
2021
|
Jay Parrish Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,945
-3.03%
|
$180,570
$26.32 P/Share
|
|
Jan 04
2021
|
Jay Parrish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,945
+2.94%
|
$6,945
$1.49 P/Share
|
|
Dec 24
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,500
+22.25%
|
$9,500
$1.53 P/Share
|
|
Dec 22
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
3,805
-13.83%
|
$117,955
$31.19 P/Share
|
|
Dec 22
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,805
+12.15%
|
$3,805
$1.53 P/Share
|
|
Dec 08
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
3,805
-13.83%
|
$117,955
$31.27 P/Share
|
|
Dec 08
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,805
+12.15%
|
$3,805
$1.53 P/Share
|
|
Dec 01
2020
|
Jay Parrish Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,945
-3.03%
|
$215,295
$31.53 P/Share
|
|
Dec 01
2020
|
Jay Parrish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,945
+1.5%
|
$6,945
$1.53 P/Share
|
|
Nov 27
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,930
-11.0%
|
$87,900
$30.0 P/Share
|
|
Nov 27
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,930
+9.91%
|
$2,930
$1.53 P/Share
|
|
Nov 27
2020
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+11.58%
|
$0
$0.86 P/Share
|
|
Nov 24
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,340
-8.99%
|
$63,180
$27.29 P/Share
|
|
Nov 24
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,340
+8.25%
|
$2,340
$1.53 P/Share
|